Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial

INTRODUCTION: Turoctocog alfa is a recombinant, B domain‐truncated factor VIII (FVIII) approved for patients with haemophilia A. AIM: To evaluate the safety and efficacy of turoctocog alfa in previously untreated patients (PUPs) with severe haemophilia A. METHODS: Guardian 4 was a multicentre, multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaish, Hassan, Matsushita, Tadashi, Belhani, Meriem, Jiménez‐Yuste, Víctor, Kavakli, Kaan, Korsholm, Lars, Matytsina, Irina, Philipp, Claire, Reichwald, Kirsten, Wu, Runhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028046/
https://www.ncbi.nlm.nih.gov/pubmed/31816159
http://dx.doi.org/10.1111/hae.13883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028046/
https://www.ncbi.nlm.nih.gov/pubmed/31816159
http://dx.doi.org/10.1111/hae.13883

Ejemplares similares